Property | Value |
?:abstract
|
-
Severe SARS-CoV-2 infection is linked to the presence of autoantibodies against multiple targets, including phospholipids and type-I interferons. We recently identified activation of an autoimmune-prone B cell response pathway as correlate of severe COVID-19, raising the possibility of de novo autoreactive antibody production during the antiviral response. Here, we identify autoreactive antibodies as a common feature of severe COVID-19, identifying biomarkers of tolerance breaks that may indicate aggressive immunomodulation.
|
is
?:annotates
of
|
|
?:creator
|
|
?:doi
|
-
10.1101/2020.10.21.20216192
|
?:doi
|
|
?:journal
|
-
medRxiv_:_the_preprint_server_for_health_sciences
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/d2dee8b8b68a5dc9736433ba0fd02448722923a6.json
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
is
?:relation_isRelatedTo_publication
of
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Broadly-targeted autoreactivity is common in severe SARS-CoV-2 Infection
|
?:type
|
|
?:year
|
|